|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correction: Monitoring <i>EGFR</i>-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
|
31069018 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Peripheral blood sampling for detection of EGFR T790M in cell-free circulating tumour (ct) DNA in TKI-resistant EGFR mutant (EGFRm) lung cancer is now standard.
|
31027703 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study.
|
31407509 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells.
|
30866688 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
|
31393074 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
|
30885357 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we demonstrate that apigenin combined with gefitinib inhibits multiple oncogenic drivers such as c-Myc, HIF-1α, and EGFR, reduces Gluts and MCT1 protein expression, and inactivates the 5' adenosine monophosphate-activated protein kinase (AMPK) signaling, which regulates glucose uptake and maintains energy metabolism, leading to impaired energy utilization in EGFR L858R-T790M-mutated H1975 lung cancer cells.
|
30967777 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S.
|
31761448 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation.
|
29290255 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
|
30268468 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
|
30268468 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation.
|
29290255 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
|
30268468 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |